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Abstract
Immunotherapy is an important breakthrough in cancer. US Food and Drug Administration-approved immunotherapies for
cancer treatment (including, but not limited to, sipuleucel-T, ipilimumab, nivolumab, pembrolizumab, and atezolizumab)
substantially improve overall survival across multiple malignancies. One mechanism of action of these treatments is to
induce an immune response against antigen-bearing tumor cells; the resultant cell death releases secondary (nontargeted)
tumor antigens. Secondary antigens prime subsequent immune responses (antigen spread). Immunotherapy-induced anti-
gen spread has been shown in clinical studies. For example, in metastatic castration-resistant prostate cancer patients,
sipuleucel-T induced early immune responses to the immunizing antigen (PA2024) and/or the target antigen (prostatic acid
phosphatase). Thereafter, most patients developed increased antibody responses to numerous secondary proteins, several
of which are expressed in prostate cancer with functional relevance in cancer. The ipilimumab-induced antibody profile in
melanoma patients shows that antigen spread also occurs with immune checkpoint blockade. In contrast to chemotherapy,
immunotherapy often does not result in short-term changes in conventional disease progression end points (eg, progression-
free survival, tumor size), which may be explained, in part, by the time taken for antigen spread to occur. Thus, immune-
related response criteria need to be identified to better monitor the effectiveness of immunotherapy. As immunotherapy
antitumor effects take time to evolve, immunotherapy in patients with less advanced cancer may have greater clinical benefit
vs those with more advanced disease. This concept is supported by prostate cancer clinical studies with sipuleucel-T,
PSA-TRICOM, and ipilimumab. We discuss antigen spread with cancer immunotherapy and its implications for clinical
outcomes.
Immunotherapy is an important advance in cancer treatment,
highlighted as the “breakthrough of the year” by Science
Magazine in 2013 (1) and the American Society of Clinical
Oncology’s “advance of the year” in 2015 (2). Several therapies
that enhance immune responses have demonstrated improve-
ments in overall survival (OS) (1). Among the US Food and Drug
Administration (FDA)-approved agents used in cancer treat-
ment are ipilimumab for melanoma (3); nivolumab for mela-
noma (4), non-small cell lung cancer (5,6), renal cell carcinoma
(7), and Hodgkin lymphoma (8); atezolizumab for urothelial can-
cer (9); pembrolizumab for melanoma (10) and non-small cell
lung cancer (11); and sipuleucel-T for prostate cancer (12).
Sipuleucel-T is an autologous cellular immunotherapy that tar-
gets prostatic acid phosphatase (PAP) and is approved in the
United States for the treatment of patients with asymptomatic
or minimally symptomatic metastatic, castration-resistant
prostate cancer (mCRPC) (13). Additional immunotherapeutic
approaches in clinical development include cytokines such as
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interleukin-15, other vaccinations including a poxvirus-based
combination regimen, adoptive cell transfer (including chimeric
antigen receptor-engineered T-cells), and blockade of immune
checkpoints (14–20).
Immunotherapies differ in a number of ways from conven-
tional chemotherapy as they are not directly cytotoxic to the tu-
mor; instead, these therapies aim to engage the immune
system to generate antitumor activity (21). Immunotherapies as
a class are often associated with statistically significant im-
provements in OS but not in progression-free survival (PFS) (22),
although benefits in reducing tumor progression are often ob-
served (2,23). For example, in mCRPC patients, sipuleucel-T sta-
tistically significantly reduced the risk of death compared with
control (hazard ratio [HR]¼ 0.78, 95% confidence interval [CI]¼ 0.61
to 0.98, P ¼ .03), whereas the time to objective disease progression
was similar between groups (HR¼ 0.95, 95% CI¼ 0.77 to 1.17, P¼ .63)
(12). Ipilimumab with or without a glycoprotein 100 (gp100) peptide
vaccine statistically significantly reduced the risk of death com-
pared with gp100 alone (comparison of ipilimumab þ gp100 vs
gp100 alone: HR¼ 0.68, P< .001, comparison of ipilimumab alone vs
gp100 alone: HR¼ 0.66, P¼ .003, respectively), in patients with met-
astatic melanoma (3). However, the median PFS was similar across
the groups, ie, 2.76 (95% CI ¼ 2.73 to 2.79, ipilimumab with gp100),
2.86 (95% CI¼ 2.76 to 3.02, ipilimumab alone), and 2.76 months (95%
CI¼ 2.73 to 2.83, gp100 alone) (3).
Limited effect on PFS by immunotherapy may reflect the
time required to mount a clinically relevant immune response,
in contrast to the immediate action of cytotoxic chemotherapy
or targeted agents (eg, tyrosine-kinase inhibitors). However, the
immune response can persist long after the completion of treat-
ment (24), and may improve over time (25) and induce develop-
ment of long-lived memory cells, providing continuous
immunologic activity (26). Furthermore, unlike conventional
therapy, the immune responses induced or expanded by immu-
notherapies can spread to include new antigenic targets (27,28).
The onset and broadening of responses with immunother-
apy occurs as a result of the tumor immunity cycle (17). Tumor
cell death in response to immunotherapy may lead to the re-
lease of secondary (ie, nontargeted) tumor antigens that prime
subsequent immune responses. Antigen spread (also known as
“epitope spread,” “determinant spread,” or “antigen cascade”) is
the expansion of an immune response to secondary epitopes
that either were not part of the original therapeutic or were not
targeted by the therapy (21). This process is dynamic and may
continue to expand over time. As discussed below, responses to
immunotherapy (both vaccines and immune checkpoint modu-
lation, and likely other immune approaches) may be associated
with antigen spread.
This review outlines the concept of antigen spread in the
context of cancer immunotherapy. The implications of antigen
spread in terms of immunologic and clinical outcomes will be
discussed.
Antigen Spread
In studies spanning over three decades, antigen spread has
been observed in the context of autoimmunity and infectious
disease (29–35). Cancer immunotherapy also appears to work, in
part, through antigen spread, ie, beginning with an immune
response to specific target antigens that broadens over time to
additional antigens expressed within the tumor (Figure 1) (21).
Mechanistically, this phenomenon likely occurs when an initial
antitumor immune response (eg, from a therapeutic anticancer
vaccine or from T-cell reactivation by immune checkpoint block-
ade) induces T-cell-mediated destruction of tumor cells. This de-
struction leads to the release of additional tumor-associated
antigens (TAAs) that may be taken up locally by antigen-
presenting cells (APCs) such as macrophages and dendritic cells.
The TAAs are processed and presented by APCs to induce B-cell-
and T-cell-mediated immune responses against the secondary
antigens (21). Figure 2 details the process of antigen spread fol-
lowing immunotherapy. An additional/alternative hypothesis for
the generation of secondary immune responses is that a success-
ful immune response against the primary/targeted antigen of an
immunotherapy may also overcome suppressive factors (17).
Thus, immunotherapy may act to amplify preexisting antibody
responses in addition to de novo generation of novel responses.
In addition, radiation, chemotherapy, and other commonly used
anticancer agents may kill tumor cells in an immunologically rel-
evant manner. This treatment can lead to immunogenic cell
death, which induces changes such as translocation of calreticu-
lin to the surface of the dead tumor cells, which mediates the
recognition and clearance of these cells by professional and
nonprofessional phagocytes, allowing for tumor-antigen pro-
cessing and presentation to the immune system (37). However,
this process may not be as efficient at generating an antitumor
immune response as a therapeutic vaccine (38).
Antigens released from the tumor may be more immuno-
genic than the antigens initially immunologically targeted (eg,
from a vaccine), and an ongoing, iterative process of antigen
spread can initiate a broader and perhaps more clinically signif-
icant immune response (21). Furthermore, antigen spread may
lead to an adaptive anticancer immune response that targets
new mutations in tumor cell antigens as they occur (21). As the
immune response broadens over time, the immune system’s
durability and adaptability may mean that the kinetic profile of
a clinical response following immunotherapy could differ from
that following cytotoxic therapy.
Evidence for Antigen Spread Mediated by
Immunotherapy
To overcome the diversity in both tumor-antigen expression
and in immune repertoire, many cancer vaccines are designed
to induce responses to multiple antigens, and there is evidence
that breadth of response is an important determinant of vaccine
efficacy. IMA901 is a novel vaccine containing 10 tumor-
associated peptides (TUMAPs) found in renal cell carcinoma
(RCC) (39). Among RCC patients immunized with IMA901, those
who responded to multiple TUMAPs had better disease control
and improved OS compared with patients who had no response
or only responded to one TUMAP. While IMA901 comprises mul-
tiple antigens, subsequent antigen spread could allow for broad-
ening of the immune response regardless of the complexity of
the agent used to generate the primary immune response.
Both preclinical and clinical data support the concept of an-
tigen spread in cancer immunotherapy, and evidence continues
to accumulate. One elegant preclinical study involved mice
bearing tumors engineered to express carcinoembryonic anti-
gen (CEA). Here, CEA-expressing (CEAþ) tumors were implanted
in one flank of experimental mice, while the opposite flank was
implanted with parental (CEA–) tumors. Mice were vaccinated
with a CEA-based vaccine, and substantial decreases in both the
CEAþ and CEA– tumors were observed. These responses were
associated with induced CD8þ T-cell responses to both CEA and
other TAAs not included in the vaccine (40). Interestingly,
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immune responses to wild-type p53 and the endogenous retro-
viral epitope gp70 were detected, with the immune response to
gp70 approximately 15 times greater than the response to CEA,
showing that responses to nontargeted antigens might be more
important than those to the initial vaccine target (41).
Clinical studies also support the concept of antigen spread.
Several of these studies involve the agent sipuleucel-T. In the
pivotal phase III study, sipuleucel-T generated peripheral im-
mune responses (either T-cell or humoral) to PA2024 (the im-
munizing antigen) and/or to PAP (the target antigen) in 79% of
patients treated with sipuleucel-T compared with 13% of pa-
tients receiving control (42), demonstrating the ability of
sipuleucel-T to induce immune responses to the original tar-
geted antigen.
Antigen spread following treatment with sipuleucel-T has
been most clearly demonstrated through studies of antibody re-
sponses in patients from the phase III pivotal trial, as well as in a
phase II study (28). These analyses involved two phases: an initial
“discovery” phase followed by a “confirmation” phase. In the ini-
tial phase, protein microarrays were used to analyze patients’ sera
for immunoglobulin G (IgG) responses. Following treatment with
sipuleucel-T, most patients showed increased antibody responses,
defined as twofold or greater elevation in antigen-specific IgG after
treatment, to a wide variety of nontarget proteins, whereas control
patients showed no such responses. Interestingly, the median
number of nontarget antigens increased from 56 antigens at two
weeks post-treatment to 162 at 10 weeks post-treatment, suggest-
ing a cascading humoral response. In the confirmation phase of
these analyses, an orthogonal assay (Luminex xMAPVR , Luminex
Corporation, Austin, TX) was used with a narrow pool of 10 anti-
gens, five with the greatest fold increases in antibody levels after
sipuleucel-T and five with known relevance to tumorigenesis or
prostate cancer. The confirmation analyses showed that
sipuleucel-T induced antibody increases to the secondary anti-
gens PSA, KLK2, LGALS3, and LGALS8, which have been shown to
be expressed at elevated levels in prostate cancer and/or to play a
role in prostate cancer development, as well as to K-Ras and E-
Ras, which are known to have functional relevance in cancer (43–
49). Response rates to individual secondary antigens ranged from
28% to 44% in the phase III study, with 25% of sipuleucel-T-treated
patients responding to three or more nontarget antigens. Antigen
spread was observed two weeks after sipuleucel-T treatment and
persisted for up to six months. Clinically, antibody responses to
PSA and LGALS3 were associated with improved OS in sipuleucel-
T-treated patients (P  .05) (28).
Evidence of antigen spread in response to immunotherapy
has also been reported in several other tumor types, including
metastatic breast cancer (50) and melanoma (26,51,52). Women
with metastatic breast cancer were treated with the monoclonal
antibody trastuzumab in combination with a vaccine targeting
human epidermal growth factor receptor 2 (HER2)/neu. As ex-
pected, most patients developed both helper and cytotoxic
T-cell responses to the HER2/neu peptides present in the vac-
cine. However, vaccinated patients also developed new or aug-
mented immunity against two epitopes of HER2/neu that were
not included in the vaccine: p98.15 (P ¼ .0055 vs prevaccination)
PAP
PSCA
MUC-1
PSA
Degenerating tumor expresses
different immunogenic targets
Fully activated T-cell
destroys tumor cells
Immature dendric cell phagocytoses dying tumor
cell along with a transfer of tumor-specific antigens
Mature dendric cells present tumor-specific
antigens to T-cells
Dying
tumor
cells
Newly activated tumor-specific T-cells form in
greater concentration and variationA D
E
B C
Figure 1. The process of antigen spread. A) An initial immune response is prompted following immunotherapy, releasing other antigens from dying tumor cells. B)
Dendritic cells act as antigen-presenting cells (APCs), processing the “free” antigens, including neoantigens, and presenting these to T-cells. C) The APCs prime T-cells
specific to antigens released from the tumor cells, increasing the breadth of the immune response. D) The newly activated tumor-specific T-cells form in greater con-
centration and variation. E) The activated T-cells then attack the tumor cells. Thus, while the initial therapy may target one antigen, a broader adaptive antitumor im-
mune response may ensue. MUC-1 ¼mucin 1; PAP ¼ prostatic acid phosphatase; PSA ¼ prostate-specific antigen; PSCA ¼ prostate stem cell antigen.
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and p776.15 (P ¼ .0006). In a subset of patients, increased T-cell
responses were also observed following vaccination against
several nontarget antigens, including insulin-like growth factor-
binding protein 2 (P ¼ .0973), p53 (P ¼ .1282), and topoisomerase
II-a (P ¼ .0111). These results are similar to the preclinical work
described previously; both intramolecular and intermolecular
antigen spread is evident in treated patients. This study in pa-
tients with metastatic breast cancer also included a substantial
follow-up phase. During a median follow-up of 36 months, most
patients maintained the level of immunity reported at the end
of the immunization period for both target and new antigens,
and approximately 25% of patients developed further immune
responses (50). In a notable case study, a patient with metastatic
melanoma had a durable remission after vaccination with
melanoma-associated antigen (MAGE), but had only a low-level
anti-MAGE cytolytic T-cell (CTL) response (26,51). Using T-cell
receptor b (TCRb) cDNA libraries, very few vaccine-specific CTLs
were found in regressing metastases, but several TCRb se-
quences were identified to correspond to nonvaccine tumor an-
tigens. Further TCRb analyses of T-cells from tumor-infiltrating
lymphocytes led to the identification of a CD8 clone that specifi-
cally lysed autologous melanoma cells. The target antigen was
caseinolytic protein, a mitochondrial enzyme mutated in the tu-
mor to produce a neoantigen. Thus, in this patient, tumor rejec-
tion effectors were CTL responses to nonvaccine tumor-specific
antigens, and this antigen spread was involved in tumor regres-
sion (26,51). Another recent study of adoptive cellular therapy
combined with CTLA-4 blockade demonstrated antigen spread
in patients with a durable tumor response (52). Collectively,
these data highlight both the persistence of an antitumor im-
mune response and the concept of late, ongoing antigen spread.
Cancer immunotherapy also encompasses agents that func-
tion by blocking negative costimulatory molecules in the immu-
nological synapse that inhibit an antitumor response. The
1. Antigen-presenting cells
 in skin-antigen uptake
2. Antigen presentation
 in lymph nodes
3. Tumor attack
4. Cross-presentation of
 multiple tumor antigens
 in draining lymph nodes
5. Broadened immune
 response: antigen
 spread/antigen cascade
Figure 2. Antigen spread following treatment with immunotherapy (36). Adapted (with permission of Springer) from: Jochems C, Schlom J, Gulley JL. Novel technologies
for vaccine development. TRICOM poxviral-based vaccines for the treatment of cancer. In: Lukashevich IS, Shirwan H, eds. Vienna: Springer; 2014:291–328. Original cap-
tion: Fig. 10. 1 Schematic overview of TRICOM vaccines showing the tumor antigen gene and the genes for the three costimulatory molecules LFA-3, ICAM-1, and B7-1
that are inserted within the virus. The vaccine is prepared and administered “off the shelf.” 1: Subcutaneous administration leads to antigen uptake by antigen-pre-
senting cells (APC) in the skin. 2: Antigen presentation occurs in the draining lymph nodes, activating antigen-specific T cells. 3: Tumor sites are attacked by antigen-
specific cytotoxic (CD8þ) T cells. 4: Tumor cell lysis leads to cross-presentation of multiple tumor antigens in the draining lymph nodes (antigen spread/antigen cas-
cade). 5: Antigen cascade leads to activation of additional antigen-specific T-cells, which increases the breadth and quite possibly the clinical activity of the antitumor
response.
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immune response to these agents may also be characterized by
the targeting of multiple antigens. Among these agents, collec-
tively referred to as immune checkpoint blockers, the monoclo-
nal antibody ipilimumab was the first-in-class T-cell
potentiator for metastatic melanoma (53). Ipilimumab (anti-
CTLA-4) blocks the interaction between cytotoxic T-lymphocyte
antigen 4 (CTLA-4) and B7 molecules, resulting in T-cell activa-
tion and subsequent objective antitumor responses in certain
patients. To better understand the antigens targeted in patients
treated with ipilimumab, potential cancer neoantigens were
identified by DNA sequencing of tissue samples from mela-
noma patients treated with ipilimumab (54). A high mutational
load was statistically significantly correlated with improved OS,
suggesting that the breadth of an antitumor immune response
has clinical significance. To more closely quantify specific CD8
T-cell responses, two patient-specific neoantigens were as-
sessed. For one of these neoantigens, there was no detectable T-
cell response at seven weeks after initiation of ipilimumab; at
24 weeks, however, a strong response was observed (54). These
data suggest an evolving response to a neoantigen. While it is
unclear if this broader response is due to increased activation of
immune cells (direct broadening) or more opportunities for im-
mune cells to kill tumor cells and release antigens in an immu-
nologically relevant manner (tumor immunity cycle-mediated
broadening), there are data suggesting that a broader response
may be clinically relevant following immune checkpoint block-
ade as well as after vaccination (55,56).
Delayed Clinical Response to Immunotherapy
A long-term class effect of immunotherapies is an improvement
in OS without short-term changes in conventional measures of
disease progression (22). This seemingly paradoxical dissocia-
tion between the two end points likely reflects the time it takes
to mount an effective immune response and for that response
to evolve into a more clinically relevant response, eg, the time it
takes for antigen spread to occur (Figure 3).
Although T- and B-cell responses to immunotherapy (ie, im-
mune responses) can be detected in the blood relatively early in
treatment, these initial responses may not be sufficient to delay
radiographic progression and substantially increase PFS. The
association of the kinetics of response to immunotherapy vs
conventional therapy was examined using data from several
clinical trials with either chemotherapy, androgen-deprivation
therapy (ADT), or immunotherapy with a vaccine in mCRPC
(57–60). These analyses showed that chemotherapy reduced tu-
mor burden quickly after treatment initiation, but effects were
frequently short-lived after treatment cessation (Figure 4A). PSA
kinetics during chemotherapy indicated tumor growth regres-
sion while on treatment; however, upon treatment cessation,
the regrowth trajectory reverted back to the pretreatment
growth rate (57,58). With immunotherapy, PSA kinetics were
not changed immediately by treatment; however, there was an
apparent slowing of disease progression as indicated by an OS
much greater than predicted by this model (Figure 4A). This
modeling confirmed the clinical outcomes reported and sug-
gested that, particularly if started earlier in the course of the
disease, immunotherapy may lead to substantially longer OS by
slowing the disease trajectory (Figure 4B) (60).
The pivotal phase III study of sipuleucel-T in mCRPC pa-
tients showed similar persistent treatment benefits. Initial re-
sults showed a 4.1-month improvement in median survival
(25.8 months in the sipuleucel-T group vs 21.7 months in the
placebo group, HR¼ 0.78, 95% CI ¼ 0.61 to 0.98, P¼ .03) (12), and
the 36-month survival probability was 31.7% in the sipuleucel-T
group vs 23.0% in the placebo group, with differences in survival
becoming apparent at six months following the start of treat-
ment. As was the case for the studies above, no statistically sig-
nificant improvement in time to objective disease progression
was observed for sipuleucel-T. Combined post hoc analyses of
the three phase III sipuleucel-T trials showed other measures
consistent with a delayed treatment effect. While time to
disease-related pain (TDRP) was not statistically significantly
delayed between treated and control groups (median TDRP ¼
5.6 months for sipuleucel-T vs 5.3 months for control, HR¼ 0.82,
95% CI ¼ 0.62 to 1.09, P ¼ .170), the 12-month pain-free rates
were 39.3% with sipuleucel-T vs 18.9% with control (61).
Moreover, time to first use of opioid analgesics (TFOA) was
statistically significantly delayed with sipuleucel-T (median
TFOA ¼ 12.6 months for sipuleucel-T vs 9.7 months for control,
HR¼ 0.76, 95% CI ¼ 0.58 to 0.99, P ¼ .038). These data suggest an
increasing impact of sipuleucel-T on end points that occur later
in the disease course, as pain develops prior to the use of opioid
analgesics (Figure 3).
Studies with other immunotherapies have reported similar
delayed treatment effects. Data from 40 patients with mCRPC
receiving PSA-TRICOM (a vector-based vaccine) indicated that
tumor growth rates, based on PSA doubling time, were not
reduced until day 80 relative to baseline (median difference
Administration of
immunotherapy
Time
Initial
immune
response
Relative
anticancer
activity
Antigen
spread
Slowing
tumor
marker
kinetics
(eg, PSA)
Radiographic
progression
OS
Clinical
progression
(TDRP      TFOA) 
Figure 3. The anticancer activity of immunotherapy increases over time. Schematic representing progression and broadening of response over time following treat-
ment with cancer-targeting immunotherapy. Antigen spread leads to more relevant targets (eg, neoantigens) for a given patient, and this highly individualized preci-
sion response could lead to improved clinical activity. Furthermore, with subsequent treatment, the immune response may be further boosted as tumor cells are killed
or modulated in an immunogenic manner, which translates into improving clinical activity over time. OS ¼ overall survival; PSA ¼ prostate-specific antigen; TDRP ¼
time to disease-related pain; TOFA ¼ time to first opioid analgesic.
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¼ –0.04 log PSA/month, interquartile range ¼ –0.08 to 0.01, P ¼
.02) (62). A phase II, randomized double-blind study in patients
with mCRPC treated with PSA-TRICOM failed to demonstrate an
improvement in PFS compared with control (15). However, a sta-
tistically significant difference favoring PSA-TRICOM was re-
ported for OS (25.1 vs 16.6 months, respectively, estimated
HR¼ 0.56, 95% CI ¼ 0.37 to 0.85, P ¼ .0061). In patients with colo-
rectal cancer, treatment with the PANVAC vaccine (a poxviral-
based vaccine targeting CEA and MUC-1) was associated with a
similar delayed pattern of response (63). Here, OS improved
with PANVAC vaccine after two years compared with controls
(median not reached vs 44.1 months, 95% CI ¼ 36.2 to 63.4, re-
spectively, P < .0001). However, the two-year recurrence-free
survival rate was similar compared with controls (21.9 months,
95% CI ¼ 16.9 to 38.8, vs 25.7 months, 95% CI ¼ 20.0 to 37.2,
respectively).
Similar delayed kinetics of benefit likely occur with immune
checkpoint–blocking agents. In a phase III, randomized. placebo-
controlled trial comparing ipilimumab plus dacarbazine compared
with dacarbazine alone, median PFS was similar in the two groups
based on the week 12 assessment. However, a statistically signifi-
cant difference in OS was observed (11.2 months, 95% CI ¼ 9.4 to
13.6, for ipilimumab þ dacarbazine vs 9.1 months, 95% CI ¼ 7.8 to
10.5, for dacarbazine alone; HR for death ¼ 0.72, 95% CI ¼ 0.59
to 0.87, P < .001). The higher survival rates for the ipilimumab þ
dacarbazine group persisted at three years compared with dacar-
bazine alone (20.8% vs 12.2%) (64). Consistent with this delayed
and persistent benefit, a pooled analysis of 12 studies of ipilimu-
mab for the treatment of melanoma reported a median OS of 11.4
months (95% CI¼ 10.7 to 12.1) and noted that the OS curve pla-
teaus at around year 3 and extends to year 10 (65). Other studies of
ipilimumab-treated patients support the notion of delayed benefit.
Some patients initially categorized as partial responders (n¼ 10)
were later categorized as complete responders (n¼ 5), and the av-
erage time to a complete response was 30 months (66). An im-
provement in OS without improvement in median PFS has been
seen with PD1 inhibition, also suggesting that this observation
may be a class effect of immunotherapy (5).
These observations highlight the concept that traditional
clinical trial end points (tumor response by traditional response
evaluation criteria in solid tumors, PFS) may not adequately re-
flect the survival benefits gained from immunotherapy.
Consideration for extending the duration of clinical studies
with immunotherapies may be necessary to adequately quan-
tify their effects and/or adapt current response criteria, includ-
ing immune-related response criteria (67).
Immunotherapy in Early Disease States
Because the clinical antitumor effects of immunotherapy may
take time to evolve, it follows naturally that treatment with im-
munotherapy earlier in the disease course should yield greater
clinical benefit. Indeed, a subset analysis of the pivotal phase III
trial of sipuleucel-T demonstrated that with decreasing baseline
PSA (used as a surrogate for disease severity), both OS and OS
benefit relative to control improved (68). The median OS in pa-
tients in the lowest baseline PSA quartile (22.1 ng/mL) was 41.3
months (sipuleucel-T) vs 28.3 months (placebo; difference ¼
13.0 months, HR¼ 0.51, 95% CI¼ 0.31 to 0.85). For patients in the
highest baseline PSA quartile (>134 ng/mL), median OS was 18.4
vs 15.6 months for sipuleucel-T and placebo, respectively (dif-
ference ¼ 2.8 months, HR¼ 0.84, 95% CI¼ 0.55 to 1.29) (68).
Therefore, patients in the lowest baseline PSA quartile appeared
to derive the greatest benefit from treatment with sipuleucel-T
vs control. Consistent with these observations, patients with
lower lactate dehydrogenase values and better performance
status also experienced greater benefit from sipuleucel-T com-
pared with patients with more advanced disease. Furthermore,
patients with low tumor burden are generally less immunosup-
pressed both systemically and in the tumor microenvironment
(69). This concept is supported by a recent study of ipilimumab
in prostate cancer (70). In a post hoc analysis of this study, pa-
tients with favorable prognostic factors at baseline (ie, alkaline
phosphatase concentration <1.5x upper limit of normal, hemo-
globin levels 11.0 g/mL, no visceral metastases) had statisti-
cally significantly prolonged OS with ipilimumab compared
with placebo, whereas in patients with at least one adverse
prognostic factor, ipilimumab did not prolong OS (70). Taken to-
gether, these data support the concept that patients with less
advanced disease may have a more robust and effective
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Figure 4. Tumor growth rates with immunotherapy (vaccine) and chemotherapy
(cytotoxic therapy). A) Tumor growth rate with no therapy (dotted black line),
with cytotoxic therapy (blue line), and with vaccine (red line), demonstrating
the slow yet prolonged response with immunotherapy resulting from immune
response activation (red line) and a short-term tumor reduction with chemo-
therapy (blue line). B) Initiating immunotherapy in early-stage disease may en-
hance the effects of immunotherapy (line b), whereas in later-stage disease the
effects could be minimal (line a). Green arrows denote treatment initiation;
crosses denote death (60). Adapted (with permission of Oxford University Press)
from: Schlom J. Therapeutic cancer vaccines: Current status and moving for-
ward. J Natl Cancer Inst. 2012;104(8):599–613.
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immunologic response to therapy, allowing more time for anti-
gen spread and associated survival benefits to be observed.
Future Considerations
Further studies examining antigen spread following treatment
with immunotherapy may be useful in not only understanding
the full benefits to be gained from current treatments, but also
in identifying other TAAs that may be appropriate targets for
the development of immunotherapies. In addition, a detailed
exploration of the clinical kinetics of immunotherapy should
provide information of potential value in assisting clinical trial
design and decision-making. If the hypothesis that immuno-
therapy has a delayed effect on the tumor growth curve is vali-
dated, treating earlier with immunotherapies may result in
improved outcomes (60,71). This observation is supported by
analyses that indicate that patients with a lower tumor burden
have a differentially better clinical response to immunotherapy
than those with a high tumor burden (68,70,72,73).
As our understanding of the mechanisms associated with
cancer immunotherapies expands, future research will likely
focus on four key concepts: 1) Combination regimens: The dispa-
rate properties of immunotherapy and conventional chemother-
apy (targeting the tumor vs the immune system; timing of
response and potential for resistance) provide a strong rationale
for combining immunotherapy with cytoreductive therapy. In
addition, conventional therapy can lead to tumor cell death,
which weakens the mechanisms of tumor immune evasion and
can enhance the ability of an activated immune system to recog-
nize and control subsequent tumor growth (37,74). 2) Sequence
of agents: The concept that the relative sequence of therapy may
have immunological implications was examined in a random-
ized phase II study evaluating the optimal sequencing of
sipuleucel-T and ADT in men with biochemically recurrent pros-
tate cancer at high risk of developing metastases (sipuleucel-T
combined with androgen deprivation therapy [STAND],
NCT01431391) (24). Data from STAND indicate that cellular and
humoral responses to PA2024 statistically significantly increased
following sipuleucel-T treatment compared with baseline, and
that these responses were sustained at all postdosing time points
through 24 months (P < .001). Sipuleucel-T given before, rather
than after, ADT initiation resulted in greater PA2024-specific T-
cell proliferation. Interestingly, sipuleucel-T-mediated antigen
spread was observed with both treatments and was maintained
through 12 months (24). 3) Combining vaccination with immune
checkpoint blockade: While immune checkpoint blockers have
shown promise, patients with no underlying immune response
appear to be much less likely to benefit (75). Thus, vaccines may
possibly convert a patient who is unlikely to respond into one
more likely to respond to an immune checkpoint inhibitor (76–
78). 4) Biomarkers: Identifying and validating biomarkers of re-
sponse are important factors in early confirmation that patients
are responding to treatment. Such biomarkers may be useful
both in guiding the timing and selection of subsequent therapy
and in making more reliable determinations of the success or
failure of novel immunotherapy agents in early-stage clinical tri-
als. Some progress has been made in identifying potential bio-
markers. The trials with sipuleucel-T have identified antibody
responses to the immunogen, and transient increases in serum
eosinophil count and IgG responses to PSA and LGALS3 have
been linked to OS (12,28,79). In vitro measures of immune activa-
tion in the sipuleucel-T product (cumulative APC activation, APC
number, and total nucleated cell count) and antigen-specific
immune responses to sipuleucel-T have also been shown to cor-
relate with OS in patients with mCRPC (42). Similarly, an anti-
body response to a glycan is associated with improved OS in
patients treated with PSA-TRICOM (80).
Conclusion
Antigen spread following treatment with immunotherapy can
evoke robust, durable, and adaptable immune responses
against tumors over an extended time period (3,12).
Understanding the process of antigen spread, and thus the
mode of action of immunotherapies, may help explain the
greater improvements in efficacy observed in longer-term clini-
cal study outcomes compared with short-term studies (eg, OS
vs PFS) (3,12,42,70). Although immunotherapy has led to major
clinical advances in the past several years, we continue to learn
more about antigen spread and the mechanism of these treat-
ments. In addition, we are exploring how to fully integrate and
optimize their use with our current and emerging armory
against cancer. Thus, the coming years promise to accelerate
our understanding of how to further optimize patient
outcomes.
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